Survodutide vs Semaglutide
Comparing Boehringer Ingelheim's dual GLP-1/glucagon agonist survodutide with single-target GLP-1 agonist semaglutide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Survodutide
Dossier overview
Semaglutide
Dossier overview
Overview
Survodutide (BI 456906) is Boehringer Ingelheim’s investigational dual GLP-1/glucagon receptor agonist, while semaglutide is an FDA-approved GLP-1 receptor agonist. Survodutide’s additional glucagon activity may offer enhanced metabolic benefits including greater effects on liver fat.
Mechanism Comparison
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| Target Receptors | GLP-1 + Glucagon | GLP-1 only |
| Receptor Activity | Dual agonist | Single agonist |
| Glucagon Effect | Agonist | None |
| Unique Feature | Liver-targeted metabolism | Proven CV benefit |
Why Glucagon Agonism?
Glucagon receptor activation may provide:
- Enhanced hepatic lipid oxidation
- Increased energy expenditure
- Greater reduction in liver fat
- Potential for MASH treatment
Evidence Comparison
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| Development Phase | Phase 3 | FDA Approved |
| Human Trials | Multiple Phase 2/3 | Extensive (STEP, SUSTAIN, SELECT) |
| MASH Data | Positive Phase 2 | Limited |
| CV Outcomes | Not yet studied | SELECT trial positive |
Weight Loss Data
Phase 2 Obesity Trial Results
| Metric | Survodutide 4.8mg | Semaglutide 2.4mg (STEP 1) |
|---|---|---|
| Weight Loss | ~18-19% | ~15% |
| Trial Duration | 46 weeks | 68 weeks |
| Population | Obesity | Obesity |
Note: Cross-trial comparisons have limitations; head-to-head data not yet available.
MASH/NASH Focus
Survodutide has shown promising results for metabolic dysfunction-associated steatohepatitis (MASH):
| Outcome | Survodutide Phase 2 |
|---|---|
| MASH Resolution | Up to 83% (highest dose) |
| Fibrosis Improvement | Significant vs placebo |
| Liver Fat Reduction | Greater than GLP-1 alone |
This is a key differentiator - the glucagon component appears to provide enhanced liver benefits.
Regulatory Status
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| FDA Status | Investigational | Approved (Ozempic, Wegovy) |
| Indications | In development | T2D, Obesity, CV risk |
| MASH Pathway | Phase 3 ongoing | Not pursued for MASH |
| Expected Approval | TBD (2025-2026) | Already approved |
Side Effect Profile
| Effect | Survodutide | Semaglutide |
|---|---|---|
| GI Effects | Common (nausea, vomiting) | Common |
| Appetite Suppression | Strong | Strong |
| Heart Rate Increase | Observed | Observed |
| Hypoglycemia | Low risk | Low risk |
Glucagon’s hyperglycemic effect may partially offset GLP-1’s glucose-lowering, potentially affecting the diabetes indication.
Administration
| Aspect | Survodutide | Semaglutide |
|---|---|---|
| Route | Subcutaneous injection | SC injection + Oral |
Key Differences
- Dual mechanism: Survodutide adds glucagon agonism to GLP-1 effects
- Liver focus: Glucagon component drives enhanced liver fat reduction
- MASH indication: Survodutide being developed specifically for MASH
- Approval status: Semaglutide is approved; survodutide is investigational
- CV evidence: Semaglutide has proven cardiovascular benefit (SELECT trial)
Summary
- Survodutide offers dual GLP-1/glucagon mechanism with promising MASH data and potentially greater weight loss
- Semaglutide is FDA-approved with extensive safety data and proven CV benefit
- Glucagon agonism provides enhanced liver fat reduction but may complicate diabetes dosing
- Head-to-head trials would be needed to definitively compare efficacy
This comparison is for educational purposes only. Survodutide is investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.